早产儿视网膜病变抗VEGF药物治疗研究进展
Research Progress on Anti-VEGF Drug Ther-apy for Retinopathy of Prematurity
DOI: 10.12677/ACM.2023.135996, PDF,   
作者: 夏 韵：重庆医科大学附属儿童医院眼科，儿童发育疾病研究教育部重点实验室，重庆；皮练鸿*：国家儿童健康与疾病临床医学研究中心，重庆
关键词: 早产儿视网膜病变；抗VEGF药物；玻璃体腔注射；Retinopathy of Prematurity； Anti-VEGF Drugs； Intravitreal Injection
摘要: 早产儿视网膜病变(Retinopathy of Prematurity, ROP)是一种发育性血管增殖性病变，发生于视网膜血管化不完全的早产儿的视网膜，是儿童严重视力障碍的重要原因。血管内皮生长因子(VEGF)是眼部病理性新生血管形成和血管通透性的重要介质，以VEGF为靶点的玻璃体腔内注射治疗的广泛使用使儿童玻璃体视网膜疾病的治疗发生了革命性的变化，是眼科和儿科基础及临床研究关注热点。本文就ROP抗VEGF药物治疗研究进展及存在问题做一综述。
Abstract: Retinopathy of prematurity (ROP) is a developmental angioproliferative lesion that occurs in the retina of premature infants with incomplete retinal vascularization and is an important cause of severe visual impairment in children. Vascular endothelial growth factor (VEGF) is an important mediator of ocular pathological neovascularization and vascular permeability, and the widespread use of intravitreal injection therapy targeting VEGF has revolutionized the treatment of children’s vitreoretinal diseases, and is a focus of basic and clinical research in ophthalmology and pediatrics. This article reviews the research progress and existing problems of ROP anti-VEGF drug treatment.
文章引用：夏韵, 皮练鸿. 早产儿视网膜病变抗VEGF药物治疗研究进展[J]. 临床医学进展, 2023, 13(5): 7128-7134. https://doi.org/10.12677/ACM.2023.135996

参考文献

[1] Wang, H. (2016) Anti-VEGF Therapy in the Management of Retinopathy of Prematurity: What We Learn from Repre-sentative Animal Models of Oxygen-Induced Retinopathy. Eye and Brain, 2016, 81-90. [Google Scholar] [CrossRef] 
[2] Mintz-Hittner, H.A., Kennedy, K.A. and Chuang, A.Z. (2011) Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. New England Journal of Medicine, 364, 603-615. [Google Scholar] [CrossRef] 
[3] Simpson, J.L., Melia, M., Yang, M.B., et al. (2012) Current Role of Cryotherapy in Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology, 119, 873-877. [Google Scholar] [CrossRef] [PubMed]
[4] Hubbard III, G.B., Cherwick, D.H. and Burian, G. (2004) Lens-Sparing Vitrectomy for Stage 4 Retinopathy of Prematurity. Ophthalmology, 111, 2274-2277. [Google Scholar] [CrossRef] [PubMed]
[5] Repka, M.X., Tung, B., Good, W.V., et al. (2006) Outcome of Eyes Developing Retinal Detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Ar-chives of Ophthalmology, 124, 24-30. [Google Scholar] [CrossRef] [PubMed]
[6] Stahl, A., Lepore, D., Fielder, A., et al. (2019) Ranibizumab versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity (RAINBOW): An Open-Label Randomised Controlled Trial. Lancet, 394, 1551-1559. [Google Scholar] [CrossRef] 
[7] Eldweik, L. and Mantagos, I.M. (2016) Role of VEGF Inhi-bition in the Treatment of Retinopathy of Prematurity. Seminars in Ophthalmology, 31, 163-168. [Google Scholar] [CrossRef] [PubMed]
[8] Chan-Ling, T., Gole, G.A., Quinn, G.E., Adamson, S.J. and Darlow, B.A. (2018) Pathophysiology, Screening and Treatment of ROP: A Multi-Disciplinary Perspective. Progress in Retinal and Eye Research, 62, 77-119. [Google Scholar] [CrossRef] [PubMed]
[9] Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angio-genesis. The American Journal of Pathology, 146, 1029-1039.
[10] Prager, G.W., Breuss, J.M., Steurer, S., Mihaly, J. and Binder, B.R. (2004) Vascular Endothelial Growth Factor (VEGF) Induces Rapid Prourokinase (Pro-uPA) Activation on the Surface of Endothelial Cells. Blood, 103, 955-962. [Google Scholar] [CrossRef] [PubMed]
[11] Mizukami, Y., Kohgo, Y. and Chung, D.C. (2007) Hypoxia In-ducible Factor-1–Independent Pathways in Tumor Angiogenesis. Clinical Cancer Research, 13, 5670-5674. [Google Scholar] [CrossRef] 
[12] Goswami, B., Goyal, M., Beri, S., et al. (2015) Role of Se-rum Levels of Vascular Endothelial Growth Factor and Its Receptor in Retinopathy of Prematurity. Iranian Journal of Pediatrics, 25, e2373. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, J. and Smith, L.E.H. (2007) Retinopathy of Prematurity. Angiogenesis, 10, 133-140. [Google Scholar] [CrossRef] [PubMed]
[14] Smith, L.E.H. (2008) Through the Eyes of a Child: Understanding Retinopathy through ROP the Friedenwald Lecture. Investigative Ophthalmology & Visual Science, 49, 5177-5182. [Google Scholar] [CrossRef] [PubMed]
[15] Tran, K.D., Cernichiaro-Espinosa, L.A. and Berrocal, A.M. (2018) Management of Retinopathy of Prematurity—Use of Anti-VEGF Therapy. Asia-Pacific Journal of Ophthalmology, 7, 56-62.
[16] Wu, A.-L. and Wu, W.-C. (2018) Anti-VEGF for ROP and Pediatric Retinal Diseases. Asia-Pacific Journal of Ophthalmology, 7, 145-151. [Google Scholar] [CrossRef] 
[17] Kang, H.G., Choi, E.Y., Byeon, S.H., et al. (2018) Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatom-ical Outcomes. Korean Journal of Ophthalmology, 32, 451-458. [Google Scholar] [CrossRef] [PubMed]
[18] Kong, L., Bhatt, A.R., Demny, A.B., et al. (2015) Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants with Retinopathy of Prematurity. Investigative Oph-thalmology & Visual Science, 56, 956-961. [Google Scholar] [CrossRef] [PubMed]
[19] Spandau, U. (2013) What Is the Optimal Dosage for Intravitreal Bevacizumab for Retinopathy of Prematurity? Acta Ophthalmologica, 91, e154. [Google Scholar] [CrossRef] [PubMed]
[20] Wallace, D. K. (2016) Retinopathy of Prematurity: An-ti-VEGF Treatment for ROP: Which Drug And What Dose? Journal of AAPOS: The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus, 20, 476-478.
[21] Geloneck, M.M., Chuang, A.Z., Clark, W.L., et al. (2014) Refractive Outcomes Following Bevacizumab Monotherapy Compared with Conventional Laser Treatment: A Randomized Clinical Trial. JAMA Ophthalmology, 132, 1327-1333. [Google Scholar] [CrossRef] [PubMed]
[22] Nicoară, S.D., Nascutzy, C., Cristian, C., et al. (2015) Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity. Journal of Ophthalmology, 2015, Article ID: 102582. [Google Scholar] [CrossRef] [PubMed]
[23] Hoerster, R., Muether, P., Dahlke, C., et al. (2013) Serum Concentra-tions of Vascular Endothelial Growth Factor in an Infant Treated with Ranibizumab for Retinopathy of Prematurity. Acta Ophthalmologica, 91, e74-e75. [Google Scholar] [CrossRef] [PubMed]
[24] 早产儿视网膜病变眼科管理对策委员会(日本眼科学会, 日本视网膜玻璃体学会, 日本小儿眼科学会, 日本眼科医会). 对于早产儿视网膜症的抗VEGF疗法的指南[J/OL]. 日本眼科学会杂志, 2020, 124(12).
https://www.nichigan.or.jp/member/journal/guideline/detail.html?%20ItemId=325&dispmid=909, 2023-05-05.
[25] Sankar, M.J., Sankar, J. and Chandra, P. (2018) Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Treatment of Retinopathy of Prematurity. Cochrane Database of Systematic Reviews, No. 1. Article No. CD009734. [Google Scholar] [CrossRef] 
[26] Stewart, M.W., Rosenfeld, P.J., F Penha, F.M., et al. (2012) Pharmacokinetic Rationale for Dosing Every 2 Weeks versus 4 Weeks with Intravitreal Ranibizumab, Bevaci-zumab, and Aflibercept (Vascular Endothelial Growth Factor Trap-Eye). Retina, 32, 434-457. [Google Scholar] [CrossRef] 
[27] Sukgen, E.A., Söker, G., Koçluk, Y. and Gülek, B. (2017) Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity. European Journal of Ophthalmology, 27, 751-755. [Google Scholar] [CrossRef] [PubMed]
[28] Stahl, A., Sukgen, E.A., Wu, W.-C., et al. (2022) Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Random-ized Clinical Trial. JAMA, 328, 348-359. [Google Scholar] [CrossRef] [PubMed]
[29] Vedantham, Va. (2019) Intravitreal Aflibercept Injection in Indian Eyes with Retinopathy of Prematurity. Indian Journal of Ophthalmology, 67, 884-888. [Google Scholar] [CrossRef] 
[30] Salman, A.G. and Said, A.M. (2015) Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity. Ophthalmic Research, 53, 15-20. [Google Scholar] [CrossRef] [PubMed]
[31] Bai, Y., Nie, H., Wei, S., et al. (2019) Efficacy of Intravitreal Conbercept Injection in the Treatment of Retinopathy of Prematurity. The British Journal of Ophthalmology, 103, 494-498. [Google Scholar] [CrossRef] [PubMed]
[32] Wu, Z., Zhao, J., Lam, W., et al. (2022) Comparison of Clinical Outcomes of Conbercept Versus Ranibizumab Treatment for Retinopathy of Prematurity: A Multicentral Pro-spective Randomised Controlled Trial. The British Journal of Ophthalmology, 106, 975-979. [Google Scholar] [CrossRef] [PubMed]
[33] Autrata, R., Krejčířová, I., Šenková, K., et al. (2012) In-travitreal Pegaptanib Combined with Diode Laser Therapy for Stage 3+ Retinopathy of Prematurity in Zone I and Poste-rior Zone II. European Journal of Ophthalmology, 22, 687-694. [Google Scholar] [CrossRef] [PubMed]
[34] Pertl, L., Steinwender, G., Mayer, C., et al. (2015) A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLOS ONE, 10, e0129383. [Google Scholar] [CrossRef] [PubMed]
[35] Huang, Q. and Zhao, P. (2018) Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity. Annals of Eye Science, 2, Article No. 47. [Google Scholar] [CrossRef] 
[36] Azad, R., Gilbert, C., Gangwe, A.B., et al. (2020) Retinopathy of Prematurity: How to Prevent the Third Epidemics in Developing Countries. Asia-Pacific Journal of Ophthalmology, 9, 440-448. [Google Scholar] [CrossRef] 

为你推荐